IDH1 and acute myeloid leukemia: In randomized phase-III trials on previously untreated elderly non-fit AML patients these regimens significantly enhanced composite CR rates (AZA/VEN: 66.4% vs. AZA: 28.3; AZA/IVO: 54% vs. AZA: 16%) and median OS (AZA/VEN: 14.7 vs. AZA: 9.6; AZA/IVO: 29.3 vs. AZA: 7.9 months) in unselected AML and IDH1 mutated AML patients, respectively [101, 102].